Form 4: Intuitive Surgical Director Sells Shares Under 10b5-1 Trading Plan

Amy L. Ladd, a director at Intuitive Surgical, sold 150 shares of common stock at $566.6 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Amy L. Ladd, a director at Intuitive Surgical, executed a sale of 150 shares of the company's common stock.
• The sale occurred on January 28, 2025, at a price of $566.6 per share.
• This transaction was conducted under a pre-established trading plan that complies with SEC Rule 10b5-1.
• The trading plan is set to expire on July 25, 2025.
• Following the transaction, Ms. Ladd directly owns 671 shares of Intuitive Surgical stock.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by a director under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Risks

• Sales by insiders can sometimes be perceived negatively by the market, although this sale was under a pre-arranged plan.

Future Outlook

The director's trading plan will expire on July 25, 2025, which may result in further transactions.

Industry Context

Insider transactions are a normal part of the market, and sales under 10b5-1 plans are common for executives and directors to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Sales by directors are common across the industry, and the use of 10b5-1 plans is a standard practice for executives at companies like Intuitive Surgical, which is similar to practices at other large medical device companies such as Medtronic and Stryker.
• These plans allow for scheduled sales to avoid any appearance of trading on non-public information, which is a common practice across the S&P 500.

Stakeholder Impact

• The sale is unlikely to have a significant impact on stakeholders, as it was a small transaction under a pre-arranged plan.

Key Dates

Keywords

insider trading, stock sale, 10b5-1 plan, Intuitive Surgical, ISRG, director, Amy L. Ladd